The company develops the Butterfly device, a first-line interventional therapy for benign prostatic hyperplasia (BPH). Its minimally invasive, reversible prostatic retraction device mechanically retracts the lateral lobes of the prostate. The device aims to restore natural urinary flow in patients suffering from the symptoms of BPH.
Butterfly Medical designed its device to conform to the natural anatomy of the prostate. The device aims to restore urine flow without cutting, burning or removing tissue.
In January, the company said it completed the final 12-month follow-up for all patients in a study of the device. It currently holds CE mark but remains investigational in the U.S.
According to Butterfly Medical, the funding supports its therapeutic approach and competitive positioning. It now looks to pursue the FDA regulatory pathway and global commercialization.
New and existing investors contributed to the funding, including the European Innovation Council (EIC), Junson Capital, MedVenture and New Rhein Healthcare Investors.
“The success of this financing round, which exceeded our target, validates both the clinical potential and significant market opportunity for the Butterfly prostatic retraction device,” said Patrick MacCarthy, CEO of Butterfly Medical. “With our pivotal trial now complete and U.S. regulatory filings underway, our focus is now on preparing for commercialization. We look forward to working with the FDA to provide men suffering from BPH with a new solution designed to improve their quality of life.”
Butterfly represents one of many companies vying for an edge in BPH treatment
BPH continues to draw innovation from various areas of medtech. ProVerum and Zenflow announced FDA approvals for their implant-based technologies that treat BPH in December 2025. Robotic technology developer Procept then launched its BPH-treating system internationally and Prodeon won FDA clearance for its nitinol device for BPH.
Yesterday, Rivermark Medical announced $20 million in funding as it advances a BPH treatment. The company aims to redefine the treatment of the condition through its FloStent platform.
Histotripsy pioneer HistoSonics also recently began a study using its therapy in BPH treatment.
